Calls for papers
-
Prescriptions for Zomig nasal spray increased 23% in 2014 compared to 2013, Impax Laboratories said, helping to offset a major decrease in revenues for the Impax Pharmaceuticals division after the 2013 loss of exclusivity for… Read more . . .
-
Boehringer Ingelheim has presented data from five Phase 3 trials of tiotropium Respimat for the treatment of asthma at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data come from… Read more . . .
-
Savara Pharmaceuticals has announced positive results from a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. In the 28-day trial, patients… Read more . . .
-
The FDA has approved Meda’s Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of seasonal allergic rhinitis in children aged 6-11 “who require treatment with both components,” the company said. Dymista was approved for… Read more . . .
-
Aegis Therapeutics has announced that the US Patent and Trademark Office has awarded the company US Patent No. 8,927,497, which covers a method “for non-invasive delivery of anti-seizure drugs via a simple metered nasal spray”… Read more . . .
-
Mumbai-based Elder Pharmaceuticals has announced the introduction of a line of over-the-counter “inhalers for nasal congestion.” The intranasal products will be sold under the Solo brand, a range of products that also includes a pain… Read more . . .
-
Dance Biopharm has announced the completion of a $9.5 million private placement that will fund clinical trials of its Dance 501 inhaled insulin. The Phase 2 program for Dance 501 is complete, according to the… Read more . . .
-
Lupin Pharmaceuticals has announced the launch of the InspiraChamber valved holding chamber after it acquired exclusive US rights to the device from InspiRX. The InspiraChamber is being sold as part of a package with pediatric… Read more . . .
-
AstraZeneca gets temporary injunction to stop Actavis sales of generic version of Pulmicort Respules
The United States Court of Appeals for the Federal Circuit has granted AstraZeneca’s request for a temporary injunction stopping Actavis from further sales of its budesonide inhalation suspension, according to Actavis. AstraZeneca has appealed the… Read more . . .
-
The FDA has granted Adapt Pharma Fast Track designation for its intranasal naloxone for the treatment of opioid overdose, the company said. Adapt Pharma licensed the product from Lightlake Therapeutics in December 2014. In the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA